The Roseman, Tarte, Harrow and Shaffer Families President’s Distinguished Professorship

Lynn Roseman, Karen Tarte, Amy Harrow and Sheri Shaffer GoodmanEstablished in 2016, this President’s Distinguished Professorship is awarded to a faculty member at the Perelman School of Medicine who is focused on blood cancer research.

Four sisters—Lynn Roseman, Karen Tarte, Amy Harrow, and Sheri Shaffer Goodman—joined forces to create the Professorship. They follow the philanthropic tradition of their parents, Jerome and Maxine Goodman, and bring the Goodman family’s support of the Abramson Cancer Center to a second generation.

The families are also inspired by the groundbreaking work of the immunotherapy research community at Penn, whose clinical trials are yielding promising results for many patients with certain types of intractable blood cancers.

President’s Distinguished Professorships are awarded to eminent faculty members with research and teaching expertise in areas identified by Penn’s President as high priorities. The creation of President’s Distinguished Professorships at the Perelman School of Medicine has been supported by the challenge gift of Penn University Trustees and Penn Medicine Board members George A. Weiss and Richard W. Vague.


 

Edward A. StadtmauerCurrent Chairholder
Edward A. Stadtmauer, MD

Edward A. Stadtmauer, MD is Co-Leader, Hematologic Malignancies research program and Section Chief for Hematologic Malignancies, appointed the Roseman, Tarte, Harrow, and Shaffer Families President’s Distinguished Professor in 2016. Dr. Stadtmauer earned his medical degree and completed his fellowship at the Perelman School of Medicine and performed his residency at the Bronx Municipal Hospital.

Dr. Stadtmauer is board-certified in internal medicine, hematology, and medical oncology with areas of clinical expertise, including blood cancer, bone marrow transplantation, multiple myeloma, and stem cell transplantation. He leads clinical trials in many of these disease areas and is widely published on the subjects of acute and chronic leukemia, autologous bone marrow transplantation, and multiple myeloma. His leadership has brought the division to new heights, including securing more than five FDA approvals in the last few years. Dr. Stadtmauer’s writings have appeared in peer-reviewed journals such as Annals of Internal Medicine, Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, and New England Journal of Medicine, among others.